Alectinib (CH5424802) is a highly selective, orally active and potent ALK inhibitor with IC50 of 1.9 nM. Alectinib (CH5424802) also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
Alectinib (CH5424802) is a highly selective, orally active and potent ALK inhibitor with IC50 of 1.9 nM. Alectinib (CH5424802) also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
Alectinib (CH5424802) is a highly selective, orally active and potent ALK inhibitor with IC50 of 1.9 nM. Alectinib (CH5424802) also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
Alectinib (CH5424802) is a highly selective, orally active and potent ALK inhibitor with IC50 of 1.9 nM. Alectinib (CH5424802) also inhibits ALK F1174L and ALK R1275Q with IC50s of 1 nM and 3.5 nM, respectively. Alectinib demonstrates effective central nervous system (CNS) penetration.
Alemtuzumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that is directed against the 21-28 kDa cell surface glycoprotein CD52. Alemtuzumab does not cross-react with mouse CD52, making in vivo studies in wild-type mice unfeasible.
Alemtuzumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that is directed against the 21-28 kDa cell surface glycoprotein CD52. Alemtuzumab does not cross-react with mouse CD52, making in vivo studies in wild-type mice unfeasible.
Alemtuzumab is a recombinant DNA-derived humanized IgG1 kappa monoclonal antibody that is directed against the 21-28 kDa cell surface glycoprotein CD52. Alemtuzumab does not cross-react with mouse CD52, making in vivo studies in wild-type mice unfeasible.
Alendronate (Fosamax) is a farnesyl diphosphate synthase inhibitor with IC50 of 460 nM.
Alendronate (Fosamax) is a farnesyl diphosphate synthase inhibitor with IC50 of 460 nM.
Alendronic acid is a bisphosphonate and farnesyl diphosphate synthase (FDPS) inhibitor that inhibits osteoclast-mediated bone resorption. Alendronic acid is used in studies related to postmenopausal osteoporosis, malignant hypercalcemia and Paget's disease.
Alendronic acid is a bisphosphonate and farnesyl diphosphate synthase (FDPS) inhibitor that inhibits osteoclast-mediated bone resorption. Alendronic acid is used in studies related to postmenopausal osteoporosis, malignant hypercalcemia and Paget's disease.
Alendronic acid is a bisphosphonate and farnesyl diphosphate synthase (FDPS) inhibitor that inhibits osteoclast-mediated bone resorption. Alendronic acid is used in studies related to postmenopausal osteoporosis, malignant hypercalcemia and Paget's disease.